Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123371 | PMC |
| http://dx.doi.org/10.1016/j.ajp.2021.102675 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Early Results of Implementing Rapid Methadone Titration for Hospitalized Patients: A Case Series.
J Gen Intern Med
January 2025
University of California, San Francisco, CA, USA.
Objectives: With the increase in illicit fentanyl use in the USA, hospitals face challenges managing opioid withdrawal and opioid use disorder (OUD). To improve opioid withdrawal and OUD treatment among hospitalized patients with daily fentanyl use, we developed a rapid methadone titration (RMT) protocol. We describe development, implementation, and outcomes during the first 12 weeks.
View Article and Find Full Text PDFPatient Challenges in Utilization of Methadone to Treat Opioid Use Disorder and Perspectives on a Solution for Improved Security and Convenience in Take-home Dosing.
Innov Clin Neurosci
December 2024
Mr. Timberlake is with Berkshire Biomedical Corporation in Dallas, Texas.
Background: Methadone is commonly utilized to treat opioid use disorder (OUD). Requirements to visit an opioid treatment provider (OTP) clinic for methadone treatment limits access to treatment, impacts quality of life, and reduces OUD treatment program retention. The Computerized Oral Prescription Administration (COPA) system is a dual-biometric dispensing device for take-home dosing that could reduce the impacts of methadone administration on patients and clinic staff.
View Article and Find Full Text PDFThe impact of Covid-19 on harm reduction policies in Iran: an interrupted time series analysis.
Harm Reduct J
January 2025
Department of Anesthesiology, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran.
Background: The global emergence of the Covid-19 pandemic in 2019 posed unprecedented challenges to healthcare systems, disrupting routine services and necessitating swift adaptations. Harm reduction programs, vital for addressing substance use-related health risks, faced unique challenges during the pandemic, impacting vulnerable populations. This study focuses on the repercussions of Covid-19 on harm reduction policies in Iran, specifically examining the distribution of condoms, syringes, and methadone to high-risk individuals attending Triangle Centers.
View Article and Find Full Text PDFRacial and Ethnic Differences in Long-Term Outcomes among Individuals with Opioid Use Disorder at Opioid Treatment Programs.
J Racial Ethn Health Disparities
December 2024
Department of Psychiatry and Biobehavioral Sciences at the David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Objectives: Racial and ethnic differences in long-term outcomes associated with medications for opioid use disorder (MOUD) are poorly understood.
Methods: The present analyses were based on 751 participants with opioid use disorder (OUD) who were initially recruited from opioid treatment programs located in California, Connecticut, Oregon, Pennsylvania, and Washington and participated in a randomized controlled trial and at least one follow-up interview. 9.
Addiction treatment and harm reduction programs in prisons: lessons from Iran.
Int J Prison Health (2024)
December 2024
Department of addiction, School of behavioural sciences and mental health (Tehran Institute of Psychiatry), Iran University of Medical Sciences, Tehran, Iran.
Purpose: Substance use disorder is one of the most prevalent health issues among prison populations. In this regard, addiction treatment and harm reduction programs have been implemented in Iranian prisons since 2002. The purpose was to describe the practical experience of implementing harm reduction programs in Iran's prisons, emphasizing the impact of policy decisions on it.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!